Shares of NuVasive, Inc. (NASDAQ:NUVA) have been assigned a consensus recommendation of “Hold” from the twenty-one analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $67.63.
NUVA has been the topic of a number of recent research reports. Needham & Company LLC lowered their price objective on NuVasive from $69.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, August 1st. Royal Bank of Canada boosted their price objective on NuVasive to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday. Robert W. Baird raised NuVasive from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $60.00 to $82.00 in a research note on Thursday, September 27th. ValuEngine lowered NuVasive from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $58.00 price objective on shares of NuVasive in a research note on Friday, October 19th.
In other news, insider Matthew Link sold 1,200 shares of the company’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $62.01, for a total value of $74,412.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 8,671 shares of company stock worth $538,741. Corporate insiders own 1.20% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in shares of NuVasive by 163.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,469 shares of the medical device company’s stock valued at $175,000 after purchasing an additional 1,533 shares during the last quarter. Honkamp Krueger Financial Services Inc. acquired a new position in shares of NuVasive in the 3rd quarter valued at $183,000. GSA Capital Partners LLP acquired a new position in shares of NuVasive in the 3rd quarter valued at $209,000. Zions Bancorporation acquired a new position in shares of NuVasive in the 3rd quarter valued at $225,000. Finally, Strs Ohio lifted its stake in shares of NuVasive by 45.5% in the 2nd quarter. Strs Ohio now owns 3,200 shares of the medical device company’s stock valued at $166,000 after purchasing an additional 1,000 shares during the last quarter.
Shares of NUVA traded up $0.03 during trading hours on Thursday, hitting $62.40. 410,115 shares of the stock were exchanged, compared to its average volume of 725,058. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of 32.67, a PEG ratio of 1.88 and a beta of 0.78. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.83 and a current ratio of 3.45. NuVasive has a 12-month low of $44.62 and a 12-month high of $72.41.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Tuesday, October 30th. The medical device company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.62 by ($0.06). The company had revenue of $271.30 million for the quarter, compared to analyst estimates of $265.70 million. NuVasive had a return on equity of 13.87% and a net margin of 2.24%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.52 EPS. On average, analysts predict that NuVasive will post 2.18 earnings per share for the current year.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.